---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268101"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:42:02.008618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO reports Q3 2025 net loss $61.9M; pipeline advances with key milestones

## Summary
- Net loss $61.9M ($1.20/sh) vs $59.6M ($1.17/sh) in Q3 2024; revenue $29.7M (+23% YoY).
- Cash, equivalents $302M as of Sep 30, 2025; cash runway into early 2027.
- RGX-202 Duchenne pivotal enrollment complete (n=30); topline early Q2 2026, BLA mid-2026.
- RGX-121 (MPS II) PDUFA date Feb 8, 2026; CSF biomarker reduction >80% sustained at 1 year.
- Sura-vec wet AMD pivotal enrollment complete (n=1,200+); topline Q4 2026.

## SEC filing metadata
- accession: 0001193125-25-268101
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/0001193125-25-268101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268101
- JSON: https://secwatch.observer/filing/0001193125-25-268101.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.